Immune Mechanisms in Uveitis

  • Ling Chen
  • Lynn K. Gordon
Part of the Essentials in Ophthalmology book series (ESSENTIALS)


Ocular Inflammation Sympathetic Ophthalmia Experimental Autoimmune Uveitis Experimental Autoimmune Uveoretinitis Anterior Chamber Associate Immune Deviation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Streilein JW (1995) Unraveling immune privilege. Science 270:1158–1159PubMedGoogle Scholar
  2. 2.
    Ohta K, Wiggert B, Taylor AW, Streilein JW (1999) Effects of experimental ocular inflammation on ocular immune privilege. Invest Ophthalmol Vis Sci 40:2010–2018PubMedGoogle Scholar
  3. 3.
    Willermain F, Caspers-Velu L, Nowak B, Stordeur P, Mosselmans R, Salmon I, Velu T, Bruyns C (2002) Retinal pigment epithelial cells phagocytosis of T lymphocytes: possible implication in the immune privilege of the eye. Br J Ophthalmol 86:1417–1421CrossRefPubMedGoogle Scholar
  4. 4.
    Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189–1192PubMedGoogle Scholar
  5. 5.
    Boyd SR, Young S, Lightman S (2001) Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 46:209–233PubMedGoogle Scholar
  6. 6.
    Caspi RR (1999) Immune mechanisms in uveitis. Springer Semin Immunopathol 21:113–124PubMedGoogle Scholar
  7. 7.
    Caspi RR (2002) Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21:197–208Google Scholar
  8. 8.
    Pennesi G, Caspi RR (2002) Genetic control of susceptibility in clinical and experimental uveitis. Int Rev Immunol 21:67–88CrossRefPubMedGoogle Scholar
  9. 9.
    Chan CC, Mochizuki M, Nussenblatt RB, Palestine AG, McAllister C, Gery I, Benezra D (1985) Lymphocyte-T subsets in experimental autoimmune uveitis. Clin Immunol Immunopathol 35:103–110CrossRefPubMedGoogle Scholar
  10. 10.
    Wacker WB, Donoso LA, Kalsow CM, Yankeelov JA, Organisciak DT (1977) Experimental allergic uveitis — isolation, characterization, and localization of a soluble uveito-pathogenic antigen from bovine retina. J Immunol 119:1949–1958PubMedGoogle Scholar
  11. 11.
    Fox GM, Kuwabara T, Wiggert B, Redmond TM, Hess HH, Chader GJ, Gery I (1987) Experimental autoimmune uveoretinitis (EAU) induced by retinal interphotoreceptor retinoid-binding protein (IRBP): differences between EAU induced by IRBP and by S-antigen. Clin Immunol Immunopathol 43:256–264CrossRefPubMedGoogle Scholar
  12. 12.
    Adamus G, Chan CC (2002) Experimental autoimmune uveitides: multiple antigens, diverse diseases. Int Rev Immunol 21:209–229PubMedGoogle Scholar
  13. 13.
    Keltner JL, Thirkill CE (1998) Cancer-associated retinopathy vs recoverin-associated retinopathy. Am J Ophthalmol 126:296–302CrossRefPubMedGoogle Scholar
  14. 14.
    Gery I, Chanaud NP III, Anglade E (1994) Recoverin is highly uveitogenic in Lewis rats. Invest Ophthalmol Vis Sci 35:3342–3345PubMedGoogle Scholar
  15. 15.
    Ham DI, Gentleman S, Chan CC, McDowell JH, Redmond TM, Gery I (2002) RPE65 is highly uveitogenic in rats. Invest Ophthalmol Vis Sci 43:2258–2263PubMedGoogle Scholar
  16. 16.
    Sun B, Rizzo LV, Sun SH, Chan CC, Wiggert B, Wilder RL, Caspi RR (1997) Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J Immunol 159:1004–1011PubMedGoogle Scholar
  17. 17.
    Agnello D, Lankford CS, Bream J, Morinobu A, Gadina M, O'Shea JJ, Frucht DM (2003) Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 23:147–161CrossRefPubMedGoogle Scholar
  18. 18.
    Egwuagu CE, Mahdi RM, Chan CC, Sztein J, Li W, Smith JA, Chepelinsky AB (1999) Expression of interferon-gamma in the lens exacerbates anterior uveitis and induces retinal degenerative changes in transgenic Lewis rats. Clin Immunol 91:196–205CrossRefPubMedGoogle Scholar
  19. 19.
    Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, Caspi RR (1997) IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 158:5997–6005PubMedGoogle Scholar
  20. 20.
    Rizzo LV, Miller-Rivero NE, Chan CC, Wiggert B, Nussenblatt RB, Caspi RR (1994) Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest 94:1668–1672PubMedGoogle Scholar
  21. 21.
    Rizzo LV, Morawetz RA, Miller-Rivero NE, Choi R, Wiggert B, Chan CC, Morse HC III, Nussenblatt RB, Caspi RR (1999) IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol 162:2613–2622PubMedGoogle Scholar
  22. 22.
    Rosenbaum JT, Kievit P, Han YB, Park JM, Planck SR (1998) Interleukin-6 does not mediate endotoxin-induced uveitis in mice: studies in gene deletion animals. Invest Ophthalmol Vis Sci 39:64–69PubMedGoogle Scholar
  23. 23.
    Miyamoto N, Mandai M, Suzuma I, Suzuma K, Kobayashi K, Honda Y (1999) Estrogen protects against cellular infiltration by reducing the expressions of E-selectin and IL-6 in endotoxin-induced uveitis. J Immunol 163:374–379PubMedGoogle Scholar
  24. 24.
    Ohta K, Yamagami S, Taylor AW, Streilein JW (2000) IL-6 antagonizes TGF-beta and abolishes immune privilege in eyes with endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 41:2591–2599PubMedGoogle Scholar
  25. 25.
    Rizzo LV, Xu H, Chan CC, Wiggert B, Caspi RR (1998) IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol 10:807–814PubMedGoogle Scholar
  26. 26.
    Sun B, Sun SH, Chan CC, Caspi RR (2000) Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res 70:493–502PubMedGoogle Scholar
  27. 27.
    Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR (1998) Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J Immunol 161:122–127PubMedGoogle Scholar
  28. 28.
    Roberge FG, de Smet MD, Benichou J, Kriete MF, Raber J, Hakimi J (1998) Treatment of uveitis with recombinant human interleukin-13. Br J Ophthalmol 82:1195–1198PubMedGoogle Scholar
  29. 29.
    Magone MT, Whitcup SM (1999) Mechanisms of intraocular inflammation. Chem Immunol 73:90–119PubMedGoogle Scholar
  30. 30.
    Rosenbaum JT, Becker MD, Smith JR (2000) Toward new therapies for ocular inflammation. Arch Soc Esp Oftalmol 75:511–514PubMedGoogle Scholar
  31. 31.
    Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB, Chan CC (1993) Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol 67:143–150PubMedGoogle Scholar
  32. 32.
    Xu HP, Forrester JV, Liversidge J, Crane IJ (2003) Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest Ophthalmol Vis Sci 44:226–234PubMedGoogle Scholar
  33. 33.
    Prendergast RA, Iliff CE, Coskuncan NM, Caspi RR, Sartani G, Tarrant TK, Lutty GA, McLeod DS (1998) T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 39:754–762PubMedGoogle Scholar
  34. 34.
    Shimizu K, Wu GS, Sultana C, Kalra VK, Rao NA (1999) Stimulation of macrophages by retinal proteins: production of reactive nitrogen and oxygen metabolites. Invest Ophthalmol Vis Sci 40:3215–3223PubMedGoogle Scholar
  35. 35.
    Silver PB, Tarrant TK, Chan CC, Wiggert B, Caspi RR (1999) Mice deficient in inducible nitric oxide synthase are susceptible to experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 40:1280–1284PubMedGoogle Scholar
  36. 36.
    Avunduk AM, Avunduk MC, Oztekin E, Baltaci AK (2002) Characterization of T lymphocyte subtypes in endotoxin-induced uveitis and effect of pentoxifylline treatment. Curr Eye Res 24:92–98CrossRefPubMedGoogle Scholar
  37. 37.
    Shen DF, Buggage RR, Eng HC, Chan CC (2000) Cytokine gene expression in different strains of mice with endotoxin-induced uveitis (EIU). Ocul Immunol Inflamm 8:221–225CrossRefPubMedGoogle Scholar
  38. 38.
    McMenamin PG, Crewe J, Kijlstra A (1997) Resident and infiltrating cells in the rat iris during the early stages of experimental melanin protein-induced uveitis (EMIU). Ocul Immunol Inflamm 5:223–233PubMedGoogle Scholar
  39. 39.
    Broekhuyse RM, Huitinga I, Kuhlmann ED, Rooijen NV, Winkens HJ (1997) Differential effect of macrophage depletion on two forms of experimental uveitis evoked by pigment epithelial membrane protein (EAPU), and by melanin-protein (EMIU). Exp Eye Res 65:841–848CrossRefPubMedGoogle Scholar
  40. 40.
    Baggia S, Lyons JL, Angell E, Barkhuizen A, Han YB, Planck SR, Taurog JD, Rosenbaum JT (1997) A novel model of bacterially-induced acute anterior uveitis in rats and the lack of effect from HLAB* 27 expression. J Investig Med 45:295–301PubMedGoogle Scholar
  41. 41.
    Willbanks GA, Rootman DS, Jay V, Wiggert B, Chamberlain J, Inman RD (1997) Experimental autoimmune uveitis in HLA-B*27 transgenic mice. Hum Immunol 53:188–194CrossRefPubMedGoogle Scholar
  42. 42.
    Baarsma GS, Kijlstra A, Oosterhuis JA, Kruit PJ, Rothova A (1986) Association of birdshot retinochoroidopathy and HLA-A29 antigen. Doc Ophthalmol 61:267–269CrossRefPubMedGoogle Scholar
  43. 43.
    Szpak Y, Vieville JC, Tabary T, Naud MC, Chopin M, Edelson C, Cohen JH, Dausset J, de Kozak Y, Pla M (2001) Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci U S A 98:2572–2576CrossRefPubMedGoogle Scholar
  44. 44.
    Zierhut M, Mizuki N, Ohno S, Inoko H, Gul A, Onoe K, Isogai E (2003) Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 60:1903–1922CrossRefPubMedGoogle Scholar
  45. 45.
    Verity DH, Wallace GR, Vaughan RW, Stanford MR (2003) Behçet's disease: from Hippocrates to the third millennium. Br J Ophthalmol 87:1175–1183CrossRefPubMedGoogle Scholar
  46. 46.
    Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, Sakane T (1995) Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B*51 transgenic mice. Arthritis Rheum 38:426–433PubMedGoogle Scholar
  47. 47.
    Levinson RD, Park MS, Rikkers SM, Reed EF, Smith JR, Martin TM, Rosenbaum JT, Foster CS, Sherman MD, Holland GN (2003) Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci 44:653–657CrossRefPubMedGoogle Scholar
  48. 48.
    Yabuki K, Inoko H, Ohno S (2000) HLA testing in patients with uveitis. Int Ophthalmol Clin 40:19–35CrossRefPubMedGoogle Scholar
  49. 49.
    Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, Yurdakul S, Yazici H (2003) The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRefPubMedGoogle Scholar
  50. 50.
    Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T (2001) Neutrophil activation in Behçet's disease. Clin Exp Rheumatol 19:S19–S24PubMedGoogle Scholar
  51. 51.
    Leiba M, Sidi Y, Gur H, Leiba A, Ehrenfeld M (2001) Behçet's disease and thrombophilia. Ann Rheum Dis 60:1081–1085CrossRefPubMedGoogle Scholar
  52. 52.
    Kaneko S, Suzuki N, Yamashita N, Nagafuchi H, Nakajima T, Wakisaka S, Yamamoto S, Sakane T (1997) Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet's disease (BD) in Japan. Clin Exp Immunol 108:204–212CrossRefPubMedGoogle Scholar
  53. 53.
    Yang P, Ji L, Zhou H, Huang X, Xie C, Jin H, Chen L, Kijlstra A (2001) Disturbed expression of Fas/FasL on CD4(+) and CD8(+)T cells in Behçet's disease, Vogt-Koyanagi-Harada syndrome, and idiopathic anterior uveitis. Ocul Immunol Inflamm 9:185–191CrossRefPubMedGoogle Scholar
  54. 54.
    Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S (2003) Serum levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet's disease. J Dermatol 30:602–607PubMedGoogle Scholar
  55. 55.
    Raziuddin S, al Dalaan A, Bahabri S, Siraj AK, al Sedairy S (1998) Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 25:329–333PubMedGoogle Scholar
  56. 56.
    Alpsoy E, Cayirli C, Er H, Yilmaz E (1998) The levels of plasma interleukin-2 and soluble interleukin-2R in Behçet's disease: a marker of disease activity. J Dermatol 25:513–516PubMedGoogle Scholar
  57. 57.
    Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 42:1967–1974CrossRefPubMedGoogle Scholar
  58. 58.
    Kotter I, Gunaydin I, Zierhut M, Stubiger N (2004) The use of interferon alpha in Behçet disease: Review of the literature. Semin Arthritis Rheum 33:320–335CrossRefPubMedGoogle Scholar
  59. 59.
    Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, Piette JC, LeHoang P (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 8:293–301CrossRefPubMedGoogle Scholar
  60. 60.
    Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 140:404–406PubMedGoogle Scholar
  61. 61.
    Read RW (2002) Vogt-Koyanagi-Harada disease. Ophthalmol Clin North Am 15:333–341CrossRefPubMedGoogle Scholar
  62. 62.
    Inomata H, Rao NA (2001) Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131:607–614CrossRefPubMedGoogle Scholar
  63. 63.
    Kahn M, Pepose JS, Green WR, Miller J, Foos RY (1993) Immunocytologic findings in a case of Vogt-Koyanagi-Harada syndrome. Ophthalmology 100:1191–1198PubMedGoogle Scholar
  64. 64.
    Gocho K, Kondo I, Yamaki K (2001) Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 42:2004–2009PubMedGoogle Scholar
  65. 65.
    Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S (2000) Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol 165:7323–7329PubMedGoogle Scholar
  66. 66.
    Chan CC, Palestine AG, Nussenblatt RB, Roberge FG, Benezra D (1985) Anti-retinal auto-antibodies in Vogt-Koyanagi-Harada syndrome, Behçet's disease, and sympathetic ophthalmia. Ophthalmology 92:1025–1028PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Ling Chen
  • Lynn K. Gordon

There are no affiliations available

Personalised recommendations